Testing an Investigational Medication

THE PURPOSE OF THIS STUDY IS TO:

* Test if the research study drug, MK-8931, is safe when given to subjects with mild to moderate Alzheimer’s disease.
* Assess the effect of two doses of the drug, MK-8931, on the ability of subjects with mild to moderate AD to understand, reason, make judgments, and remember.
* Assess the effect of two doses of the drug, MK-8931, on the ability of subjects with mild to moderate AD to function in activities of daily living.

MK-8931 is an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration (FDA). Participants will receive either the study drug or a placebo pill (no active ingredient).

Adults 55 to 85 years old who have been diagnosed with mild to moderate Alzheimer’s disease may be eligible to participate.

Participants will be paid for time & travel related to the study. Study medication, study-related procedures and tests, and study visits will be provided at no cost.

For more information: call Marcy at 513-558-2455
or email to shidlemd@ucmail.uc.edu

Yahoo! News reports that proposed FDA guidelines may make it easier for drug companies to test Alzheimer’s treatments in people at an earlier stage, when scientists think they may have the best shot at working.
Read the Full Article.